Alan Shaw
Chairman and Chief Scientific Officer at VaxInnate Corporation
Country of Residence: United States
Alan R. Shaw, PhD, is Chairman and Chief Scientific Officer at VaxInnate Corporation where he is responsible for scientific and medical conduct of the company’s efforts to develop new vaccines incorporating pathogen associated molecular patterns. He joined VaxInnate in 2005 following a 15year career at Merck Research Laboratories where he was responsible for R&D leading to the licensure of Varivax®, ProQuad®, Zostavax®, RotaTeq® and Gardasil®.
Prior to joining Merck, Dr. Shaw was a Senior Program Executive at Biogen S.A in Geneva, Switzerland where he led projects on hepatitis B vaccines, malaria vaccines, cytokines and their inhibitors, and cell trafficking. Dr. Shaw was the Chairman of the International Federation of Pharmaceutical Manufacturers’ Association Biologicals Committee and has extensive experience in national and international vaccine development and policy matters.